These recommendations are based on clinical trial outcomes computed from treatment start.
The mean RTV < 1 between days 4 and 18 post treatment start indicates tumour shrinkage.
Nucleation sites after recrystallization heat treatment start in shear bands with subsequent growth in the direction of slip lines.
The Strategic Timing of Antiretroviral Treatment (START) trial began in March 2009.
All patients presented at treatment start a class II division 1 malocclusion with increased overjet (range 5 to 12 mm).
In 55.5% of cases the histologic diagnosis led to changes in treatment (start corticosteroids or stop antibiotic).
At follow-up 5 years after treatment start, splenic volume was 167 cm3 (right), a volume reduction of 60%%.
Early treatment start contributed to improved survival.
Thus, patients with poor response to IFNβ injections already had more active disease at treatment start.
Sixteen patients (9%) weighed less than 36 kg at the time of treatment start.
In general, pRC was inversely correlated to drug resistance at treatment start (on average ρ = −0.38).
